CMA drops probe into Merck’s Remicade discounts

The UK’s antitrust enforcer has closed its abuse of dominance investigation into Merck Sharp & Dohme’s discount scheme, despite finding no “procompetitive rationale or efficiency justification” for the conduct.


Get unlimited access to all Global Competition Review content